Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 15;13(2):792-802.
eCollection 2021.

The sodium/D-dimer ratio predicts the effect of first-line chemotherapy and prognosis in patients with advanced gastric cancer

Affiliations

The sodium/D-dimer ratio predicts the effect of first-line chemotherapy and prognosis in patients with advanced gastric cancer

Liqun Zhang et al. Am J Transl Res. .

Abstract

Background: Gastric cancer (GC) is one of the most common cancers worldwide. The survival time of patients with advanced gastric cancer (AGC) is shortened. We evaluated the role of the sodium/fibrinogen ratio (SFR) and sodium/D-dimer ratio (SDR) in predicting the first-line chemotherapy response, progression-free survival (PFS), and overall survival (OS) of patients with AGC.

Methods: A total of 304 patients with AGC were retrospectively reviewed. SDR only was selected as a potential prognostic marker for the subsequent studies in this study. Based on the cut-off value of the SDR, the patients were divided into high-SDR and low-SDR groups and investigated for their clinicopathological features, first-line chemotherapy effects and clinical outcomes.

Results: The cut-off value based on the SDR was 282.22, and the patients were divided into low-SDR (SDR ≤ 282.22) and high-SDR (SDR > 282.22) groups. The disease control rate was higher in the high-SDR group than in the low-SDR group (91.1% vs. 82.3%; P = 0.036). Patients with a high SDR had a longer median PFS and OS than those with a low SDR (PFS: 206.0 vs. 134.0 days, P < 0.001; OS: 435.0 vs. 295.5 days, P < 0.001). The SDR was an independent prognostic indicator in the multivariable analysis of PFS (P < 0.001) and OS (P = 0.004). In subgroup analyses, among the patients with normal sodium and D-dimer levels, SDR was still a reliable prognostic indicator of PFS and OS in patients with AGC (all P ≤ 0.001).

Conclusions: This study suggests that the SDR may serve as a prognostic indicator for chemotherapy outcome, PFS and OS for patients with AGC receiving first-line chemotherapy.

Keywords: Sodium/D-dimer ratio; first-line chemotherapy; gastric cancer; overall survival; prognosis; progression-free survival.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
ROC curves for the ability of pre-treatment SDR and SFR to predict OS for patients with AGC. ROC, receiver operating characteristic; SFR, sodium/fibrinogen ratio; SDR, sodium/D-dimer ratio; AGC, advanced gastric cancer.
Figure 2
Figure 2
Relationship between the (A) DCR and (B) ORR and the SDR value. The proportion of patients achieving (C) DCR and (D) ORR in the low-SDR group and high-SDR group. In the violin plots, the horizontal dotted lines indicate Q1 and Q3, and the horizontal bars within the violin indicate the median. *, P < 0.05; **, P < 0.01; ns, P > 0.05; SDR, sodium/D-dimer ratio; PD, progressive disease; SD, stable disease; DCR, disease control rate; ORR, objective response rate; Q1, first quartile; Q3, third quartile.
Figure 3
Figure 3
Kaplan-Meier estimates of (A) PFS and (B) OS in patients with low SDR and high SDR. SDR, sodium/D-dimer ratio; PFS, progression-free survival; OS, overall survival.
Figure 4
Figure 4
Subgroup analysis for the association between the SDR and PFS and OS in the subgroups stratified by (A and B) normal sodium level and (C and D) normal D-dimer level. SDR, sodium/D-dimer ratio; PFS, progression-free survival; OS, overall survival.

Similar articles

Cited by

References

    1. Sano T, Sasako M, Kinoshita T, Maruyama K. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer. 1993;72:3174–3178. - PubMed
    1. Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H, Arai K, Kodera Y, Nashimoto A. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9:51–66. - PubMed
    1. Wu H, Cai Z, Lu G, Cao S, Huang H, Jiang Y, Sun W. Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis. Tumori. 2017;103:249–254. - PubMed
    1. Greenhill C. Gastric cancer. Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer. Nat Rev Gastroenterol Hepatol. 2015;12:124. - PubMed
    1. Qi X, Liu Y, Wang W, Cai D, Li W, Hui J, Liu C, Zhao Y, Li G. Management of advanced gastric cancer: an overview of major findings from meta-analysis. Oncotarget. 2016;7:78180–78205. - PMC - PubMed

LinkOut - more resources